Fennec Pharmaceuticals Inc. (NASDAQ:FENC) concluded the trading at $8.54 on Wednesday, September 21 with a rise of 11.93% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $7.63 and 5Y monthly beta was reading -0.02 with its price kept floating in the range of $7.65 and $8.75 on the day. Considering stock’s 52-week price range provides that FENC hit a high price of $10.08 and saw its price falling to a low level of $3.82 during that period. Over a period of past 1-month, stock came adding 33.23% in its value.
With its current market valuation of $226.40 million, Fennec Pharmaceuticals Inc. is set to declare its quarterly results on Mar 28, 2022 – Apr 01, 2022. Analysts are in estimates of -$0.12 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.46 for 2022 with estimates of that growing to -$0.29 in next year. These estimates are suggesting current year growth of 31.30% for EPS and 37.00% growth next year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review FENC stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.
Digging deeper we become aware of the PEG ratio of the FENC stock which is currently positioned at 0. It further provides that stock’s current price level is 23.52% away from its 20-day simple moving average and is 25.65% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 72.11 while volatility remained at 9.03% over the past week which changes to 6.26% when measuring it over the past month. Beta is valued at 0.05, while measure of average true range or ATR is currently at 0.45. In predicting price targets of as low as $11.00 and as high as $17.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $13.00. Stock’s current price level is -28.81% above from estimated low price target while it is -99.06% below the estimated high; and even if the FENC’s share succeeded to reach the median price of $11.00, then the outlook of -28.81% could come to the excitement of the investors.
In comparing Fennec Pharmaceuticals Inc. (FENC)’s stock with other industry players reveals that stock’s current price change of 11.93% and that of -0.81% over the past 12 months is in competing position with that of Eli Lilly and Company (LLY) which saw its stock price fall by -1.74% in the last trading and went through an increase of 28.81% in past 12-month trading. Industry’s another major player Johnson & Johnson (JNJ) has fall -1.02% down in previous session, but over the past year has faced a fall of -0.76%, while Sanofi (SNY) was also down -2.95% however its price remained floating in the red at -19.19% over the same period. Fennec Pharmaceuticals Inc. has a P/E ratio of 0 against that of Eli Lilly and Company’s 47.31 while Johnson & Johnson is showing 23.74 for the same. On the other hand, the S&P 500 Index was down -1.71% in the last trading session while the Dow Jones Industrial closed the session lower at -1.70%.
Having a second look at Fennec Pharmaceuticals Inc. (NASDAQ:FENC) provides that stock’s average daily trading volume for 3 months was 70.48K, while it jumped to 0.2 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 26.05 million.
The percentage of outstanding shares held by the insiders is 0.10% while it is 43.30% for the institutional holders. The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 0.16 million which implies a short ratio of 5.01. This shows down a 0.60% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 0.21 million in the previous month. Addition of 94.09% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.